SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2020 / Today, Cofactor Genomics announced the peer-reviewed publication of an analytical validation study demonstrating the performance of its novel RNA-based immune profiling assay, ImmunoPrism®, in the April 2020 issue of the Journal of Molecular Diagnostics. The paper is the first public disclosure of the company's proprietary methods used for quantifying immune cells in the tumor microenvironment (TME).
To view the complete and interactive multimedia version of this announcement, click here
Key Takeaways
- Paper is the first public disclosure of Cofactor's proprietary methods of quantifying immune cells in the tumor microenvironment
- Cofactor technology uses less tissue and achieves higher sensitivity and specificity in detecting difficult-to-quantify cell types, such as M2 macrophages
- Analytical validation may lower barriers to adoption and make company's technology more accessible
About Cofactor Genomics
Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor's products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine. Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful.
About the Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP), seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. For more information visit: https://jmd.amjpathol.org/
Media contact for Cofactor Genomics
Mariesa Kemble
[email protected]
(608) 345-2389
Media contact for Journal of Molecular Diagnostics
Emily H. Essex
[email protected]
(240) 283-9721
SOURCE: Cofactor Genomics